Onconetix sets second 1-for-10 reverse stock split, effective November 6

Onconetix, Inc. (Nasdaq: ONCO) said its board acted on October 22, 2026 to carry out another reverse stock split of its common stock, at a ratio of one-for-ten, with the board making that determination on October 22, 2026¹. The company disclosed the move in an 8-K filed October 26, 2026, with an accompanying press release of the same date.

This is the second such action under authority stockholders granted at a special meeting held April 30, 2026, where they approved giving the board discretion to execute one or more reverse splits at ratios between 1-for-2 and 1-for-10, within one year of the meeting, so long as the combined ratio did not exceed 1-for-100¹. The company had already used part of that authority once, carrying out a 1-for-10 split effective May 21, 2026¹. Combined with the new split, the two actions together reach the full 1-for-100 ratio allowed under that stockholder approval.¹

Mechanically, the company plans to file a certificate of amendment with Delaware's Secretary of State on November 5, 2026, with the split taking effect at 12:01 a.m. Eastern on November 6, 2026, when shares are expected to begin trading split-adjusted on Nasdaq under the same ticker, ONCO, with a new CUSIP number, 68237Q500¹. The filing states that outstanding shares will fall from about 5.9 million to roughly 589,000 shares¹. No fractional shares will be issued; holders entitled to fractions will instead get cash based on the closing Nasdaq price the trading day before the split takes effect, adjusted for the split¹. The company also noted that outstanding equity awards, convertible preferred stock, and warrants will have proportional adjustments to share counts and exercise or conversion prices¹.